#1 Clinical Trials Search in Europe

Study on the Safety and Effectiveness of Alpha1H for Adults with Non-Muscle Invasive Bladder Cancer Awaiting Tumor Removal Surgery

1 1

What is this study about?

This clinical trial is focused on studying non-muscle invasive bladder cancer, a type of bladder cancer that has not spread into the muscle layer of the bladder. The study will evaluate a treatment called Alpha1H, which is a solution used for instillation directly into the bladder. The purpose of the study is to assess the safety and effectiveness of Alpha1H in patients who are waiting for surgery to remove their bladder tumor.

Participants in the study will receive either the Alpha1H treatment or a placebo. The treatment involves placing the solution into the bladder through a process called intravesical instillation, which means the solution is delivered directly into the bladder. The study will monitor how the treatment affects the cancer, including any changes in the size and shape of the tumor, and whether it causes cancer cells to shed into the urine. The study will also look at how the treatment affects the body overall, including any side effects that may occur.

The trial will include various assessments to understand the impact of Alpha1H on the cancer and the body. These assessments will involve examining the tumor tissue and urine samples to see how the treatment works at a cellular level. The study aims to provide valuable information about the potential benefits and safety of using Alpha1H for treating non-muscle invasive bladder cancer.

1 joining the study

The study involves adult patients with non-muscle invasive bladder cancer who are awaiting surgery to remove the tumor.

Participants must provide signed and dated informed consent to join the study.

Eligibility includes being 18 years or older, having a negative pregnancy test for women of childbearing potential, and using appropriate contraception methods during the study.

2 treatment administration

The study drug, Alpha1H, is administered through a process called intravesical instillation, which involves delivering the solution directly into the bladder.

Participants will receive either the Alpha1H solution or a placebo solution.

The treatment aims to evaluate the safety and effectiveness of Alpha1H in reducing tumor size and changing its shape.

3 monitoring and evaluation

Throughout the trial, adverse events will be monitored, including any local or systemic reactions to the treatment.

Vital signs, ECG, and laboratory parameters will be assessed to ensure safety.

The response of the tumor to Alpha1H will be evaluated using imaging techniques during cystoscopy, and the resected tumor will be analyzed through histopathology.

4 urine analysis

Urine samples will be collected to measure cell shedding, which serves as a biomarker for tumor response.

Changes in protein markers and apoptotic changes in shed cells will be analyzed before and after the Alpha1H instillation.

5 tissue analysis

Biopsies will be taken to assess tissue changes using histopathology and immunohistochemistry.

The uptake of Alpha1H by tumor tissue will be quantified and compared to healthy tissue.

Gene expression analysis will be conducted to study changes in cancer-associated pathways.

6 completion of the study

The study is expected to conclude by November 30, 2026.

Participants will be monitored for 30 days after the last treatment to collect data on any adverse events.

Who Can Join the Study?

  • Must have signed and dated an informed consent form, which means you agree to participate in the study after understanding what it involves.
  • Must have a type of bladder cancer called non-muscle invasive papillary bladder cancer (NMIBC), which is a cancer that has not spread into the muscle layer of the bladder. This should be confirmed by a procedure called cystoscopy, where a doctor looks inside the bladder with a special camera.
  • Must be on the waiting list for a surgery called transurethral resection of the bladder (TURB), which is a procedure to remove bladder tumors.
  • Both men and women can participate, but you must be 18 years or older.
  • If you are a woman who can have children, you must have a negative pregnancy test before joining the study.
  • If you are a woman who can have children, you must use appropriate methods of birth control during the study.
  • You must be able to hold the contents of your bladder for at least one hour.

Who Cannot Join the Study?

  • Patients who have a different type of bladder cancer that is not classified as non-muscle invasive bladder cancer. This type of cancer is limited to the inner layers of the bladder and has not spread to the muscle layer.
  • Patients who have already undergone the planned transurethral surgery. This is a procedure where a doctor removes bladder tumors using a tool inserted through the urethra.
  • Patients who are not within the specified age range for the study. The study is open to certain age groups only.
  • Patients who are part of a vulnerable population, which means they might need special protection or care.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Fefyxfuy nwcxnhyiq Mkbxv a Hcgipsq Prague Czechia

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Czechia Czechia
Not recruiting
11.12.2017

Trial locations

Investigated drugs:

Alpha1H is a medication being studied for its potential to treat non-muscle invasive bladder cancer. It is administered directly into the bladder through a process called intravesical instillation. The goal of this treatment is to evaluate its safety and effectiveness in reducing or eliminating cancer cells in patients who are awaiting surgery.

Investigated diseases:

Non-muscle invasive bladder cancer – This type of bladder cancer is characterized by the presence of cancerous cells in the bladder lining that have not yet invaded the muscle layer. It often presents with symptoms such as blood in the urine, frequent urination, or pain during urination. The disease is typically detected through imaging tests or cystoscopy, where a camera is used to view the inside of the bladder. Over time, if not managed, the cancer can progress to invade deeper layers of the bladder wall. The progression of the disease is monitored through regular follow-ups and imaging to assess any changes in the tumor’s size or characteristics.

Trial ID:
2024-514628-17-00
Protocol code:
HP002-001
Trial Phase:
Human Pharmacology (Phase I) – Other

Other Trials to Consider

  • Study of TYRA-300-B01 tablets in patients with low grade, intermediate risk non-muscle invasive bladder cancer who have FGFR3 gene changes

    Recruiting

    2 1 1
    Investigated drugs:
    France Italy Spain

  • Study of MK-3120 for patients with high-risk non-muscle invasive bladder cancer who have not received or have received BCG treatment

    Recruiting

    1 1 1
    Investigated drugs:
    Austria Belgium France Greece Italy The Netherlands +2